^
Association details:
Biomarker:HLA-A*03
Cancer:Solid Tumor
Drug Class:PD1 inhibitor
Direction:Resistant
Evidence:
Evidence Level:
Resistant: B - Late Trials
Source:
Title:

HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study

Published date:
01/01/2022
Excerpt:
HLA-A*03 was associated in an additive manner with reduced overall survival after ICI treatment in the MSK-IMPACT cohort (HR 1·48 per HLA-A*03 allele [95% CI 1·20–1·82], p=0·00022), the validation DFCI Profile cohort (HR 1·22 per HLA-A*03 allele, 1·05–1·42; p=0·0097), and in the JAVELIN Solid Tumour clinical trial for bladder cancer (HR 1·36 per HLA-A*03 allele, 1·01–1·85; p=0·047).
DOI:
10.1016/S1470-2045(21)00582-9